Clinical Cumulative Morphine Equivalent Dosing Point of Sale Edit effective January 1, 2017

Beginning January 1, 2017 most Amerigroup* Community Care Medicare Advantage plans will implement a cumulative morphine equivalent (MEq) dosing edit at the point of sale. This MEq dosing edit will identify members taking a cumulative dose that exceeds the daily dose that Amerigroup sets. This is a patient safety edit intended to reduce the risk from high dose opioid use. There is a higher risk for overdose when exceeding the set MEq dosing limit. The claim(s) will reject at the point of sale and require a prior authorization review if the cumulative dosing is over the set daily limit. Certain members may be excluded from the edit, such as members with cancer. The edit supports the CMS guidance mandating that Medicare plans implement a cumulative dosing edit. Amerigroup anticipates that this edit will impact a fairly high number of claims.

60509WPPENMUB 06/09/2016

*In New Mexico, Amerigroup Community Care of New Mexico, Inc. In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup Texas, Inc. In Washington, Amerigroup Washington, Inc.

Amerivantage is a DSNP plan with a Medicare contract and a contract with the State Medicaid program. In New Mexico: Amerivantage is an HMO with a Medicare contract. Enrollment in Amerivantage depends on contract renewal.